Studies have demonstrated the anti-glioma activity of EGFRvIII-specific CAR-T cells [99,100]; however, patients with GBM often solely express wild-type EGFR, limiting therapeutic benefits [101]. The gene discussed is EGFR; the disease is glioblastoma.